Skip to Content
Merck
CN

F5551

Hemagglutinin, Filamentous

from Bordetella pertussis, lyophilized powder

Synonym(s):

Anti-HA, FHA, Hemagglutinin, Fimbrial

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Hemagglutinin, Filamentous from Bordetella pertussis, lyophilized powder

form

lyophilized powder

mol wt

200-220 kDa

shipped in

wet ice

storage temp.

2-8°C

Quality Level

Related Categories

General description

Filamentous Hemagglutinin (FHA) from Bordetella pertussis is a major virulence-associated adhesion factor secreted by these bacteria. It contains an arginine-glycine-aspartate (RGD) sequence. FHA is a derivative of its precursor FhaB.

Biochem/physiol Actions

Filamentous Hemagglutinin (FHA) from Bordetella pertussis enables the attachment of bacteria to the epithelium of the upper respiratory tract. The arginine-glycine-aspartate (RGD) sequence mediates the binding of FHA to sulfated polysaccharides and pulmonary macrophage integrins.

Physical form

lyophilized from 0.05 M Tris HCL, pH 8, with 0.5 M sodium chloride and 5% sucrose

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

常规特殊物品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Louise De Weerdt et al.
Frontiers in immunology, 15, 1360201-1360201 (2024-03-11)
Tetanus, diphtheria, acellular pertussis (Tdap) vaccination is recommended to be administered in every pregnancy. Although the safety of this strategy has been confirmed, the immunogenicity of Tdap vaccination in two successive pregnancies has not yet been described. This study investigated
Elizabeth M Goebel et al.
PloS one, 4(8), e6778-e6778 (2009-08-27)
Although B. bronchiseptica efficiently infects a wide range of mammalian hosts and efficiently spreads among them, it is rarely observed in humans. In contrast to the many other hosts of B. bronchiseptica, humans are host to the apparently specialized pathogen

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service